Holen Sie sich die Stockscreener-App
27.53
4.84%
-1.40
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
November 9 earnings date set for Celldex Therapeutics stock - ad-hoc-news.de
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - Lelezard
Law firm investigates Celldex Therapeutics for possible breach of fiduciary duties. - Pluang
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - PR Newswire
FMR LLC and Abigail P. Johnson Reveal 10.7% Stake in Celldex Therapeutics Inc. - Kalkine Media
An investment firm reports a passive stake of 8.4 million shares in Celldex Therapeutics (CLDX). - Stock Titan
Celldex Therapeutics Inc (TCE2.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Celldex Therapeutics: Trying To Put Its Troubled History Behind It (NASDAQ:CLDX) - Seeking Alpha
Celldex reports Phase 3 success as HC Wainwright rates Celldex Therapeutics stock Buy - AD HOC NEWS
Celldex Therapeutics stock reports strong Phase 3 trial results - AD HOC NEWS
Celldex Therapeutics (NasdaqCM:CLDX) Stock Forecast & Analyst Predictions - Simply Wall Street
Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
What Do Positive Barzolvolimab Results Mean for Celldex (NASDAQ:CLDX)? - Kalkine Media
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64 - Moomoo
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success? - Yahoo Finance
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Yahoo Finance
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CLDX) 2026-09-22 - Seeking Alpha
Celldex Therapeutics upgraded to Buy after posi... - Pluang
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CLDX) 2026-09-22 - Seeking Alpha
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results - Benzinga
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Benzinga
Celldex Therapeutics Shares Fall After Phase 3 Readout Despite Positive Trial Results - Quiver Quantitative
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses - finance.yahoo.com
Celldex sinks as safety concerns cloud immune drug results - BioPharma Dive
Celldex sinks as safety concerns cloud immune drug results - finance.yahoo.com
Celldex shares slip 15% as safety concerns cloud skin drug trial win - The Economic Times
Celldex's barzolvolimab hits primary and secondary endpoints in twin Phase III CSU trials - thepharmaletter.com
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - tradingview.com
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials - finance.yahoo.com
Celldex stock falls after hives trial data (CLDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials - marketscreener.com
Celldex announces Phase 3 barzolvolimab trials meet primary and all key secondary endpoints - tradingview.com
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 - GlobeNewswire
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 - GlobeNewswire
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials - Yahoo Finance
Celldex Therapeutics stock gains as analysts target USD 56.42 - AD HOC NEWS
Celldex Reports Positive Phase 3 Results for Barzolvolimab - Intellectia AI
Celldex Therapeutics (Nasdaq:CLDX)Stock Analysis - simplywall.st
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - Eastern Progress
Celldex Therapeutics stock gains as analysts lift expectations - AD HOC NEWS
Celldex at Cantor conference: barzolvolimab data loom By Investing.com - Investing.com Canada
Celldex at Cantor conference: barzolvolimab data loom By Investing.com - Investing.com UK
Celldex to Present at Upcoming Investor Conference - The Manila Times
Celldex's investor talk will stream online Sept. 10 - Stock Titan
Celldex to Present at Upcoming Investor Conference - GlobeNewswire
Celldex to Present at Upcoming Investor Conference - Yahoo Finance
Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX - TradingView
Celldex (CLDX) Quarterly Results: Profit Per Share Clears Its Benchmark on the Day; Market Reaction - vinanet.vn
2.71%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):